PMID- 32782942
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2397-9070 (Electronic)
IS  - 2397-9070 (Linking)
VI  - 4
IP  - 4
DP  - 2020 Aug
TI  - Therapeutic strategy for the patients with coexisting gastroesophageal reflux 
      disease and postprandial distress syndrome of functional dyspepsia.
PG  - 582-588
LID - 10.1002/jgh3.12299 [doi]
AB  - BACKGROUND AND AIM: Gastroesophageal reflux disease (GERD) and functional 
      dyspepsia (FD) frequently overlap. However, no accepted treatment has yet been 
      established for such patients. This study was conducted to identify an adequate 
      initial treatment for patients with GERD accompanied by the postprandial distress 
      syndrome type of FD (FD-PDS). METHODS: Of the 150 patients newly diagnosed with 
      GERD who visited our clinic, 53 patients with the typical symptoms of both GERD 
      and FD-PDS were assessed using the modified frequency scale for the symptoms of 
      GERD and the gastroesophageal reflux and dyspepsia therapeutic efficacy and 
      satisfaction test questionnaires. Of those, 42 patients who completed 4 weeks of 
      treatment were analyzed. We compared the treatment responses between the 21 
      patients who received proton pump inhibitor (PPI) monotherapy and 21 patients who 
      received a PPI in combination with the prokinetic drug acotiamide. RESULTS: 
      Assessment of the two questionnaires revealed a marked improvement of both GERD 
      and FD symptom scores after 4 weeks of treatment in both groups. However, there 
      were no significant differences in any GERD or FD symptom scores at baseline, 
      after 4 weeks of treatment and in the symptom score change between the two 
      different treatment groups. CONCLUSION: The results of this retrospective study 
      suggest no benefit of PPI-prokinetic combination versus PPI monotherapy in adult 
      patients with FD-GERD overlap; therefore, PPI monotherapy could be an adequate 
      initial treatment for such patients.
CI  - (c) 2020 The Authors. JGH Open: An open access journal of gastroenterology and 
      hepatology published by Journal of Gastroenterology and Hepatology Foundation and 
      John Wiley & Sons Australia, Ltd.
FAU - Isshi, Kimio
AU  - Isshi K
AUID- ORCID: 0000-0001-7137-4083
AD  - Department of Gastoroenterology, Isshi Gastro-Intestinal Clinic Tokyo Japan.
AD  - Department of Endoscopy Jikei University School of Medicine Tokyo Japan.
FAU - Furuhashi, Hiroto
AU  - Furuhashi H
AD  - Department of Gastoroenterology, Isshi Gastro-Intestinal Clinic Tokyo Japan.
AD  - Department of Endoscopy Jikei University School of Medicine Tokyo Japan.
FAU - Nakada, Koji
AU  - Nakada K
AD  - Department of Gastoroenterology, Isshi Gastro-Intestinal Clinic Tokyo Japan.
AD  - Department of Laboratory Medicine The Jikei University Daisan Hospital Tokyo 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20200203
PL  - Australia
TA  - JGH Open
JT  - JGH open : an open access journal of gastroenterology and hepatology
JID - 101730833
PMC - PMC7411656
OTO - NOTNLM
OT  - acotiamide
OT  - combined therapy
OT  - functional dyspepsia
OT  - gastroesophageal reflux disease
OT  - proton pump inhibitor
EDAT- 2020/08/13 06:00
MHDA- 2020/08/13 06:01
PMCR- 2020/02/03
CRDT- 2020/08/13 06:00
PHST- 2019/08/13 00:00 [received]
PHST- 2019/12/20 00:00 [revised]
PHST- 2019/12/30 00:00 [accepted]
PHST- 2020/08/13 06:00 [entrez]
PHST- 2020/08/13 06:00 [pubmed]
PHST- 2020/08/13 06:01 [medline]
PHST- 2020/02/03 00:00 [pmc-release]
AID - JGH312299 [pii]
AID - 10.1002/jgh3.12299 [doi]
PST - epublish
SO  - JGH Open. 2020 Feb 3;4(4):582-588. doi: 10.1002/jgh3.12299. eCollection 2020 Aug.